The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time

Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from thi...

Full description

Saved in:
Bibliographic Details
Published in:Livers 2023-09, Vol.3 (3), p.325-330
Main Authors: Noverati, Nicholas, Yan, Vivian, Jun, Jay W., Halegoua-DeMarzio, Dina, Hann, Hie-Won
Format: Article
Language:English
Subjects:
Asian Americans
chronic hepatitis B
Drug dosages
Families & family life
functional cure
Hepatitis B
host response
Infections
Liver cancer
Liver cirrhosis
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93
cites cdi_FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93
container_end_page 330
container_issue 3
container_start_page 325
container_title Livers
container_volume 3
creator Noverati, Nicholas
Yan, Vivian
Jun, Jay W.
Halegoua-DeMarzio, Dina
Hann, Hie-Won
description Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.
doi_str_mv 10.3390/livers3030024
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6c14c050ebc9438c895b0634a83a21d0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6c14c050ebc9438c895b0634a83a21d0</doaj_id><sourcerecordid>2869388865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93</originalsourceid><addsrcrecordid>eNpVkUFPwzAMhSMEEtPYkXskzoWkSduE2zQxmDQBh96jNHG3TF0zkhbEvydjCMHJlvX8-dlG6JqSW8YkuevcO4TICCMk52dokpcVyzgT8vxPfolmMe5IkghKykpMkKq3gNe-3-BHvYd7PMfLsTeD873u8GIMgFcRv_oYXdMB_nDDFj-PpgMfnQU8Tyq_GSFi3Vs8JFTtUvexzbcp38MVumh1F2H2E6eoXj7Ui6ds_fK4WszXmWEVGTJBcpoMCgqStxVtRWGrIhe8sgCUG6aZaTWVrWw0FKCJ5RxoQ8BqWZZasilanbDW6506BLfX4VN57dR3wYeN0mFwybgqTQKSgkBjZBpphCwaUjKuBdM5tSSxbk6sQ_BvabdB7fwY0qZR5aKUyaUoi6TKTioT0nUCtL9TKVHHj6h_H2Ff2rx9rA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869388865</pqid></control><display><type>article</type><title>The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time</title><source>Publicly Available Content (ProQuest)</source><creator>Noverati, Nicholas ; Yan, Vivian ; Jun, Jay W. ; Halegoua-DeMarzio, Dina ; Hann, Hie-Won</creator><creatorcontrib>Noverati, Nicholas ; Yan, Vivian ; Jun, Jay W. ; Halegoua-DeMarzio, Dina ; Hann, Hie-Won</creatorcontrib><description>Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.</description><identifier>ISSN: 2673-4389</identifier><identifier>EISSN: 2673-4389</identifier><identifier>DOI: 10.3390/livers3030024</identifier><language>eng</language><publisher>Kansas City: MDPI AG</publisher><subject>Asian Americans ; chronic hepatitis B ; Drug dosages ; Families &amp; family life ; functional cure ; Hepatitis B ; host response ; Infections ; Liver cancer ; Liver cirrhosis ; Patients</subject><ispartof>Livers, 2023-09, Vol.3 (3), p.325-330</ispartof><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93</citedby><cites>FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93</cites><orcidid>0000-0001-8298-5381 ; 0000-0002-0381-8700 ; 0000-0002-8833-2362</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2869388865/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2869388865?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,25734,27905,27906,36993,44571,74875</link.rule.ids></links><search><creatorcontrib>Noverati, Nicholas</creatorcontrib><creatorcontrib>Yan, Vivian</creatorcontrib><creatorcontrib>Jun, Jay W.</creatorcontrib><creatorcontrib>Halegoua-DeMarzio, Dina</creatorcontrib><creatorcontrib>Hann, Hie-Won</creatorcontrib><title>The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time</title><title>Livers</title><description>Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.</description><subject>Asian Americans</subject><subject>chronic hepatitis B</subject><subject>Drug dosages</subject><subject>Families &amp; family life</subject><subject>functional cure</subject><subject>Hepatitis B</subject><subject>host response</subject><subject>Infections</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Patients</subject><issn>2673-4389</issn><issn>2673-4389</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVkUFPwzAMhSMEEtPYkXskzoWkSduE2zQxmDQBh96jNHG3TF0zkhbEvydjCMHJlvX8-dlG6JqSW8YkuevcO4TICCMk52dokpcVyzgT8vxPfolmMe5IkghKykpMkKq3gNe-3-BHvYd7PMfLsTeD873u8GIMgFcRv_oYXdMB_nDDFj-PpgMfnQU8Tyq_GSFi3Vs8JFTtUvexzbcp38MVumh1F2H2E6eoXj7Ui6ds_fK4WszXmWEVGTJBcpoMCgqStxVtRWGrIhe8sgCUG6aZaTWVrWw0FKCJ5RxoQ8BqWZZasilanbDW6506BLfX4VN57dR3wYeN0mFwybgqTQKSgkBjZBpphCwaUjKuBdM5tSSxbk6sQ_BvabdB7fwY0qZR5aKUyaUoi6TKTioT0nUCtL9TKVHHj6h_H2Ff2rx9rA</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Noverati, Nicholas</creator><creator>Yan, Vivian</creator><creator>Jun, Jay W.</creator><creator>Halegoua-DeMarzio, Dina</creator><creator>Hann, Hie-Won</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8298-5381</orcidid><orcidid>https://orcid.org/0000-0002-0381-8700</orcidid><orcidid>https://orcid.org/0000-0002-8833-2362</orcidid></search><sort><creationdate>20230901</creationdate><title>The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time</title><author>Noverati, Nicholas ; Yan, Vivian ; Jun, Jay W. ; Halegoua-DeMarzio, Dina ; Hann, Hie-Won</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Asian Americans</topic><topic>chronic hepatitis B</topic><topic>Drug dosages</topic><topic>Families &amp; family life</topic><topic>functional cure</topic><topic>Hepatitis B</topic><topic>host response</topic><topic>Infections</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noverati, Nicholas</creatorcontrib><creatorcontrib>Yan, Vivian</creatorcontrib><creatorcontrib>Jun, Jay W.</creatorcontrib><creatorcontrib>Halegoua-DeMarzio, Dina</creatorcontrib><creatorcontrib>Hann, Hie-Won</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Directory of Open Access Journals</collection><jtitle>Livers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noverati, Nicholas</au><au>Yan, Vivian</au><au>Jun, Jay W.</au><au>Halegoua-DeMarzio, Dina</au><au>Hann, Hie-Won</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time</atitle><jtitle>Livers</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>3</volume><issue>3</issue><spage>325</spage><epage>330</epage><pages>325-330</pages><issn>2673-4389</issn><eissn>2673-4389</eissn><abstract>Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.</abstract><cop>Kansas City</cop><pub>MDPI AG</pub><doi>10.3390/livers3030024</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8298-5381</orcidid><orcidid>https://orcid.org/0000-0002-0381-8700</orcidid><orcidid>https://orcid.org/0000-0002-8833-2362</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2673-4389
ispartof Livers, 2023-09, Vol.3 (3), p.325-330
issn 2673-4389
2673-4389
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_6c14c050ebc9438c895b0634a83a21d0
source Publicly Available Content (ProQuest)
subjects Asian Americans
chronic hepatitis B
Drug dosages
Families & family life
functional cure
Hepatitis B
host response
Infections
Liver cancer
Liver cirrhosis
Patients
title The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T23%3A23%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Long%20Game:%20A%20Functional%20Cure%20Is%20Possible%20with%20Nucleoside%20Analogues%20and%20the%20Tincture%20of%20Time&rft.jtitle=Livers&rft.au=Noverati,%20Nicholas&rft.date=2023-09-01&rft.volume=3&rft.issue=3&rft.spage=325&rft.epage=330&rft.pages=325-330&rft.issn=2673-4389&rft.eissn=2673-4389&rft_id=info:doi/10.3390/livers3030024&rft_dat=%3Cproquest_doaj_%3E2869388865%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c370t-802143881e94f71f85d752847dee14c3a3cfa19f9bae5ea0d44e1b0eda966a93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2869388865&rft_id=info:pmid/&rfr_iscdi=true